Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Sarah Kim

Assistant Professor

University of Florida

United States

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

80%

Pharmacotherapy

50%

Pharmacometrics

40%

Drug Formulation

40%

Drug Safety

30%

Patient-centered Outcomes

20%

Muscle Biology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Open

Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression

Open Date: 2023-01-25

Close Date: 2027-12-31

Grant: Close

Quantifying Clinical and Genetic Factors Influencing Rate and Severity of Mucin1 (MUC1) and Uromodulin (UMOD) Variants of Autosomal Dominant Tubulointerstitial Kidney Disease

Open Date: 2022-08-01

Close Date: 2024-07-31

Grant: Close

Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation

Open Date: 2021-09-01

Close Date: 2023-07-31

Grant: Close

A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy

Open Date: 2019-03-07

Close Date: 2020-03-06

Sarah Kim

Assistant Professor

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles15

Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progression

Use of imaging biomarkers and ambulatory functional endpoints in Duchenne muscular dystrophy clinical trials: Systematic review and machine learning-driven trend analysis

Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles

Clinical importance of changes in magnetic resonance biomarkers for Duchenne muscular dystrophy

Future Opportunities in Drug Development: American Society for Clinical Pharmacology and Therapeutics Pharmacometrics and Pharmacokinetics Community Vision

Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials

Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians

Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)

Pharmacokinetic and Pharmacodynamic Analysis of Acetaminophen and Ibuprofen Dual Therapy for Patent Ductus Arteriosus Closure in Preterm Neonates at Less Than 29 Weeks of Gestation

A randomized, cross‐over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence

Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype

Evaluating Genetic Modifiers of Duchenne Muscular Dystrophy Disease Progression Using Modeling and MRI

Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

A case study of a patient‐centered reverse translational systems‐based approach to understand adverse event profiles in drug development

Collaborators6

Stephan Schmidt

Reginald Frye

Scott Mosley

Charles Peloquin

Juan Francisco Morales

Natalia Valadares de Moraes

How do I reach out?